<DOC>
	<DOCNO>NCT00003202</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining radiation therapy chemotherapy may kill tumor cell . PURPOSE : Phase I/II trial compare effectiveness gemcitabine radiation therapy alone follow two-drug combination chemotherapy treat patient stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Gemcitabine Plus Radiation Therapy Combination Chemotherapy Treating Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose twice-weekly gemcitabine deliver concurrently thoracic radiotherapy alone follow 2 cycle induction chemotherapy patient Stage IIIA IIIB non-small cell lung cancer . - Assess toxicity concurrent thoracic radiation gemcitabine patient . - Determine effectiveness concurrent radiation gemcitabine determine complete response rate , partial response rate , time recurrence , pattern recurrence , overall survival cohort patient . OUTLINE : This alternate two arm , dose escalation , multicenter study . Arm I : Patients receive twice-weekly gemcitabine 30 minute infusion . Concurrent radiation therapy administer 5 day week 6 week . Arm II : Patients receive 2 cycle induction chemotherapy consist gemcitabine 30 minute infusion day 1 8 cisplatin IV 1 hour day 1 . Each cycle 21 day . Patients receive gemcitabine radiation therapy arm I . Cohorts 3 patient enrol treatment arm dose level gemcitabine . Toxicity arm assess independently . Once dose limit toxicity ( DLT ) observe dose level , 3 patient enrol dose level . The maximum tolerated dose ( MTD ) define dose 1 6 patient experience grade 4 toxicity , 4 6 patient experience grade 3 bad toxicity ( DLT ) . After MTD determine treatment arm , additional patient treat dose level phase II portion study . Patients follow every 3 month 2 year , every 4 month next 2 year , every 6 month thereafter . PROJECTED ACCRUAL : There approximately 24-48 patient accrue study within 1-2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IIIA IIIB nonsmall cell lung cancer unicentric inoperable , include follow cellular type : Squamous cell carcinoma Adenocarcinoma Bronchoalveolar carcinoma Large cell anaplastic carcinoma Nonsmall cell lung cancer otherwise specify Tumors may multifocal disease believe result direct spread Disease must fully accessible radiotherapy port entire prescribe dose No supraclavicular node diffuse pleural involvement No contralateral hilar disease exudative , bloody , cytologically malignant effusion Measurable disease require phase II study PATIENT CHARACTERISTICS : Age : Any age Performance status : ECOG 02 Life expectancy : At least 1 year Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin great 10 g/dL Hepatic : Bilirubin great 2.0 mg/dL Renal : BUN great 1.5 time normal Creatinine great 1.5 time normal Pulmonary : FEV1 great 1 liter except tumor negatively impact pulmonary function Other : No serious medical psychiatric illness No prior lung cancer except free disease 3 year No prior malignancy except nonmelanoma skin cancer free disease 1 year Not pregnant nursing Negative pregnancy test PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior thoracic radiotherapy Concurrent radiotherapy anatomic site allow Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
</DOC>